jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Aug. 04, 2023

Oct. 06, 2025

jRCT2011230029

33-104 : Drug Use-Results Survey of OPDIVO (Unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy)

33-104 : Drug Use-Results Survey of OPDIVO

Nakao Takafumi

Ono Pharmaceutical Co.,LTD

1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan

+81-6-6222-5501

pms_contact_ml@ono-pharma.com

Nakao Takafumi

Ono Pharmaceutical Co.,LTD

1 -5 Doshomachi 2-chome, Chuo-ku, Osaka-shi, Osaka 541-8526, Japan

+81-6-6222-5501

pms_contact_ml@ono-pharma.com

Complete

Nov. 01, 2018

Dec. 18, 2018
100

Observational

single arm study

open(masking not used)

uncontrolled control

single assignment

other

Patients with unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chemotherapy, who have recieved OPDIVO for the first time

Patients who have received OPDIVO previously

No limit
No limit

Both

Unresectable advanced/recurrent malignant pleural mesothelioma that has progressed after cancer chem

[Safety]
a) Occurrence status of adverse drug reactions and infections,
b) Factors that are considered to affect safety
c) Adverse events

Ono Pharmaceutical Co.,LTD
Not being included in the items required by GPSP Ordinance, a central IRB is not in place. The study is planned to conduct an IRB at the study site as needed.
none, Hokkaido

Nov. 15, 2018

No

none

History of Changes

No Publication date
4 Oct. 06, 2025 (this page) Changes
3 Aug. 06, 2025 Detail Changes
2 Sept. 04, 2024 Detail Changes
1 Aug. 04, 2023 Detail